Novartis AG (NVSN) — Cash Flow-to-Debt Ratio
Novartis AG (NVSN) has a Cash Flow-to-Debt Ratio of 0.05x as of March 2026, meaning its operating cash flow of MX$3.68 Billion could theoretically repay 0% of its total liabilities (MX$79.61 Billion) in one year. See Novartis AG (NVSN) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Novartis AG Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Novartis AG across 12 annual periods. For the full cash flow conversion analysis, see Novartis AG operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Novartis AG (2014–2025)
Year-by-year debt coverage analysis for Novartis AG. Check Novartis AG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (MXN) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.30x | MX$19.14 Billion | MX$64.40 Billion | ▼ -1.9% |
| 2024 | 0.30x | MX$17.62 Billion | MX$58.12 Billion | ▲ +0.6% |
| 2023 | 0.30x | MX$16.02 Billion | MX$53.20 Billion | ▲ +22.8% |
| 2022 | 0.25x | MX$14.24 Billion | MX$58.03 Billion | ▲ +4.1% |
| 2021 | 0.24x | MX$15.07 Billion | MX$63.97 Billion | ▲ +30.1% |
| 2020 | 0.18x | MX$13.65 Billion | MX$75.39 Billion | ▼ -16.5% |
| 2019 | 0.22x | MX$13.62 Billion | MX$62.82 Billion | ▲ +1.6% |
| 2018 | 0.21x | MX$14.27 Billion | MX$66.87 Billion | ▼ -0.5% |
| 2017 | 0.21x | MX$12.62 Billion | MX$58.85 Billion | ▲ +3.2% |
| 2016 | 0.21x | MX$11.47 Billion | MX$55.23 Billion | ▼ -4.9% |
| 2015 | 0.22x | MX$11.90 Billion | MX$54.43 Billion | ▼ -14.2% |
| 2014 | 0.25x | MX$13.90 Billion | MX$54.54 Billion | — |